CYP-001
Steroid-Resistant Acute Graft-Versus-Host Disease (GvHD)
Phase 2Active
Key Facts
Indication
Steroid-Resistant Acute Graft-Versus-Host Disease (GvHD)
Phase
Phase 2
Status
Active
Company
About Cynata Therapeutics
Cynata develops off-the-shelf stem cell therapies using its scalable Cymerus platform to treat inflammatory and ischemic conditions.
View full company profile